Gyre Therapeutics, Inc.

NasdaqCM:GYRE Stock Report

Market Cap: US$956.1m

Gyre Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Han Ying

Chief executive officer

US$21.1k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.2yrs
Board average tenure1.2yrs

Recent management updates

Recent updates

A Look At The Fair Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Jun 27
A Look At The Fair Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

CEO

Han Ying (58 yo)

less than a year

Tenure

US$21,078

Compensation

Dr. Han Ying, Ph D., serves as a Director of Gyre Therapeutics, Inc. since October 30, 2023 and serves as its Chief Executive Officer from January 15, 2024. Dr. Han Ying boasts more than two decades of exp...


Leadership Team

NamePositionTenureCompensationOwnership
Han Ying
CEO & Directorless than a yearUS$21.08kno data
Songjiang Ma
President & Director1.2yrsno data3.42%
$ 32.7m
Ruoyu Chen
Chief Financial Officer1.2yrsUS$308.68kno data
Weiguo Ye
Chief Operating Officer1.2yrsUS$274.62k0%
$ 0
Seline Miller
Senior Vice President of Financeno datano datano data

1.2yrs

Average Tenure

54yo

Average Age

Experienced Management: GYRE's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Han Ying
CEO & Director1.2yrsUS$21.08kno data
Songjiang Ma
President & Director1.2yrsno data3.42%
$ 32.7m
Thomas Eastling
Director2yrsUS$1.88m0%
$ 0
David M. Epstein
Directorless than a yearno datano data
Ying Luo
Chairman of the Board2yrsUS$24.74k3.31%
$ 31.6m
Renate Parry
Independent Director1.2yrsUS$19.91kno data
Gordon Carmichael
Independent Director1.2yrsUS$19.24kno data
Rodney Nussbaum
Independent Directorless than a yearno datano data

1.2yrs

Average Tenure

65yo

Average Age

Experienced Board: GYRE's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:39
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gyre Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution